Decision Analysis to Compare Treatment Strategies for Stage I/Favorable Histology Wilms Tumor

被引:13
|
作者
Frazier, A. Lindsay [1 ,2 ]
Shamberger, Robert C. [3 ]
Henderson, Tara O. [4 ]
Diller, Lisa [1 ]
机构
[1] Harvard Univ, Sch Med, Dept Pediat Oncol, Dana Farber Childrens Hosp Canc Care, Boston, MA USA
[2] Harvard Univ, Brigham & Womens Hosp, Channing Lab, Sch Med, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Dept Surg, Boston Childrens Hosp, Boston, MA 02115 USA
[4] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA
关键词
clinical trial design; decision analysis; Wilms tumor; CANCER-STUDY-GROUP; INITIAL TREATMENT; LATE MORTALITY; ACTINOMYCIN-D; VINCRISTINE; AGE; 2ND;
D O I
10.1002/pbc.22396
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Decision analysis was used to clarify differences in survival and complication rates comparing surgery alone versus surgery plus chemotherapy for Stage I, favorable histology Wilms tumor patients. Procedure. A state transition model was used to simulate treatment with nephrectomy-only, nephrectomy with adjuvant vincristine (VCR) or with vincristine plus dactinomcyin (NWTS Regimen EE4A). Rates of relapse and complications of therapy were obtained from the literature. In sensitivity analysis, the model was probed for the value(s) at which the treatment of choice changes. Results. The overall survival (OS) is essentially the same for patients treated with any of the three strategies (OSNephrectomy = 98.8%; OSEE4A = 98.8%; OSVCR = 98.6%). Rates of serious long-term complications in the surviving population are also similar across treatment strategies (nephrectomy = 1.4%; VCR = 1.2%; EE4A = 0.3%). Both the progression and salvage rates after nephrectomy-only would have to be much worse than expected for nephrectomy-only to be an unacceptable strategy. Conclusions. The differences in overall survival and rates of long-term complications between the three different initial strategies were negligible in the model. Based on this analysis, it was decided by the Children's Oncology Group that it was acceptable to continue to include nephrectomy without adjuvant chemotherapy as an experimental arm of the low risk Wilms tumor protocol with stringent eligibility criteria and close follow-up. Decision analysis can have a role in clinical trial design by making the tradeoffs between strategies more explicit. The robustness of these conclusions can be tested by widely varying the underlying assumptions. Pediatr Blood Cancer 2010;54:879 884. (C) 2010 Wiley-Liss, Inc.
引用
收藏
页码:879 / 884
页数:6
相关论文
共 50 条
  • [1] Treatment of children with stage IV favorable histology Wilms tumor: A report from the National Wilms Tumor Study Group
    Green, DM
    Breslow, NE
    Evans, I
    Moksness, J
    DAngio, GJ
    MEDICAL AND PEDIATRIC ONCOLOGY, 1996, 26 (03): : 147 - 152
  • [2] Outcome of Patients With Stage II/Favorable Histology Wilms Tumor With and Without Local Tumor Spill: A Report From the National Wilms Tumor Study Group
    Green, Daniel M.
    Breslow, Norman E.
    D'Angio, Giulio J.
    Malogolowkin, Marcio H.
    Ritchey, Michael L.
    Evans, Audrey E.
    Beckwith, J. Bruce
    Perlman, Elizabeth J.
    Shamberger, Robert C.
    Peterson, Susan
    Grundy, Paul E.
    Dome, Jeffrey S.
    Thomas, Patrick R. M.
    Kalapurakal, John A.
    PEDIATRIC BLOOD & CANCER, 2014, 61 (01) : 134 - 139
  • [3] Pulmonary metastases after nephrectomy only for small, stage I/favorable-histology Wilms’ tumor
    Toshiji Shitara
    Yoshiaki Tsuchida
    Junko Hirato
    Akira Shimada
    Hideaki Murai
    Norio Suzuki
    Minoru Kuroiwa
    Mayumi Iwakawa
    Pediatric Surgery International, 2005, 21 : 470 - 473
  • [4] Pulmonary metastases after nephrectomy only for small, stage I/favorable-histology Wilms' tumor
    Shitara, T
    Tsuchida, Y
    Hirato, J
    Shimada, A
    Murai, H
    Suzuki, N
    Kuroiwa, M
    Iwakawa, M
    PEDIATRIC SURGERY INTERNATIONAL, 2005, 21 (06) : 470 - 473
  • [5] Outcomes of relapsed favorable-histology Wilms tumor in non-clinical trial setting
    Schneller, Netta
    Daw, Najat
    Throckmorton, Whitney
    Mullen, Elizabeth
    Desmith, Kylene
    Marcarenhas, Leo
    O'Connell, Cameron
    Fernandez, Conrad V.
    Sutton, Kathryn S.
    Venkatramani, Rajkumar
    PEDIATRIC BLOOD & CANCER, 2025, 72 (01)
  • [6] WILMS-TUMOR - REDUCED-DOSE RADIOTHERAPY IN ADVANCED-STAGE WILMS-TUMOR WITH FAVORABLE HISTOLOGY
    TOBIN, RL
    FONTANESI, J
    KUN, LE
    FAIRCLOUGH, DL
    HUSTU, HO
    PAO, WJ
    DOUGLASS, EC
    WILIMAS, J
    KUMAR, APM
    JENKINS, JJ
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 19 (04): : 867 - 871
  • [7] Gene expression analysis and the risk of relapse in favorable histology Wilms' tumor
    Abdel-Monem, Mariam M.
    El-Khawaga, Omali Y.
    Awadalla, Amira A.
    Hafez, Ashraf T.
    Ahmed, Asmaa E.
    Abdelhameed, Mohamed
    Abdelhalim, Ahmed
    ARAB JOURNAL OF UROLOGY, 2023, 21 (01) : 45 - 51
  • [8] Nomogram for personalized prognostic assessment of children with favorable histology Wilms tumor: A retrospective analysis
    Wang, Zihong
    Li, Jiayi
    Liu, Pei
    Xie, Xianghui
    Song, Hongcheng
    Zhang, Weiping
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 (06) : 178.e1 - 178.e10
  • [9] P-Glycoprotein Expression, Tumor Weight, Age, and Relapse in Patients with Stage I and II Favorable-Histology Wilms' Tumor
    Plaza Teixeira, Roberto Augusto
    Odone-Filho, Vicente
    de Camargo, Beatriz
    Zerbini, Maria Claudia
    Fillipi, Renne
    Alencar, Arlaine
    Cristofani, Lilian
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2011, 28 (03) : 194 - 202
  • [10] Radiotherapy omitted in the treatment of selected children under 3 years of age with stage III favorable histology Wilms tumor
    Pachnis, A
    Pritchard, J
    Gaze, M
    Levitt, G
    Michalski, A
    MEDICAL AND PEDIATRIC ONCOLOGY, 1998, 31 (03): : 150 - 152